Home LiteratureArticle Details
PMID: 16157901 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

LRRK2 gene in Parkinson disease: mutation analysis and case control association study.

Neurology ·Vol. 65 ·No. 5 ·2005-09-13 ·Pages 696-700

Paisán-Ruíz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St George-Hyslop P, Singleton A, Rogaeva E

Abstract

In addition to the four well-confirmed genes linked to early-onset Parkinson disease (PD) (SNCA, PARKIN, DJ-1, and PINK1), mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have recently been identified in families with autosomal dominant late-onset PD. To perform mutation analysis of LRRK2 in probands of families showing dominant inheritance of PD and to conduct a case control association study to test the hypothesis that common coding variations might be associated with increased susceptibility to PD. All 51 LRRK2 coding exons were sequenced in 23 probands and the mutation frequencies were evaluated in 180 neurologically normal control subjects. For the association study the authors genotyped four coding LRRK2 polymorphisms in 250 normal control subjects and 121 patients with PD (predominantly white patients of Canadian origin), 84% of whom had age at onset before 50 years and 42% had a positive family history. The authors identified three probands with heterozygous LRRK2 mutations: two of them have the known G2019S substitution and one proband has a novel I1371V substitution. Mutation analysis of a large family demonstrated complete segregation of the G2019S with PD. However, there was no association between PD and any of the four polymorphisms at the allelic or genotypic levels (p > 0.17). Furthermore, the authors did not detect a modifying effect for any genotype or of APOE genotypes upon the age at onset in the PD group (p > 0.20). The results support the prior suggestion that LRRK2 mutations cause PD. The disease in the families reported here presents a phenotype indistinguishable from typical PD. All three families demonstrate a very variable age at onset that is not explained by APOE genotypes. The common coding variations in the LRRK2 gene neither constitute strong PD risk factors nor modify the age at onset; however, the possibility of a modest risk effect remains to be assessed in large datasets.

MeSH Terms
Adult Age of Onset Aged Aged, 80 and over Apolipoproteins E/genetics Case-Control Studies DNA Mutational Analysis Exons/genetics Family Health Gene Frequency/genetics Genetic Predisposition to Disease/genetics Genetic Testing Genotype Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Middle Aged Mutation/genetics Parkinson Disease/genetics,metabolism Polymorphism, Genetic/genetics Protein Serine-Threonine Kinases/genetics
Chemicals
Apolipoproteins E LRRK2 protein, human Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Protein Serine-Threonine Kinases
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Paisán-Ruíz C
National Institute on Aging, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, MD, USA.
Lang A E
Kawarai T
Sato C
Salehi-Rad S
Fisman G K
Al-Khairallah T
St George-Hyslop P
Singleton A
Rogaeva E
Article Info
Journal
Neurology
Abbr.
Neurology
ISSN
1526-632X
Published
2005-09-13
Pages
696-700
Language
English
Region
United States
NLM ID
0401060
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com